Professional product catalogue

Rheumatology medicines

Rheumatology medicines concern several dimensions of the musculoskeletal system, including inflammation, uric acid metabolism and bone remodelling. Anti-inflammatory agents, gout medicines and osteoporosis agents have different functions. Joint, muscle and bone do not describe one tissue or one pharmacological target. This category explains those families and their forms, distinguishing action on a painful manifestation from a mechanism directed at a particular biological process. The common musculoskeletal setting does not make every medicine interchangeable or give every product associated with joints the same regulatory status.

Anti-inflammatory medicines

Non-steroidal anti-inflammatory drugs, or NSAIDs, are distinct from corticosteroids and from analgesics without comparable anti-inflammatory action. The field contains systemic forms and local preparations associated particularly with musculoskeletal manifestations. Ibuprofen, diclofenac and other substances retain their own characteristics. This category explains mechanisms, oral or cutaneous forms and composition differences without turning the word anti-inflammatory into a shared promise of efficacy or tolerability. Related roles in pain do not erase differences in targets, formulation or documented conditions of use between individual medicines.

348 classified products

Gout medicines

Gout medicines include agents addressing inflammation and treatments acting on uric acid. These functions differ: an inflammatory joint attack and the wider setting of hyperuricaemia are not the same dimension. Colchicine, xanthine oxidase inhibitors and other families have distinct mechanisms. This category explains gout medicine families, substances and presentations without treating every analgesic used for joint pain as a specific urate-lowering agent. The disease context links several processes while leaving the pharmacological purpose and complete identity of each medicinal product distinct.

49 classified products

Osteoporosis medicines

Osteoporosis medicines act on bone remodelling through different mechanisms. Bisphosphonates and selected biological agents form part of this category's vocabulary, with specific oral or injectable presentations. Osteoporosis concerns bone fragility and fracture risk rather than simply joint pain. Understanding bone resorption, formation and molecular targets distinguishes these medicines from analgesics and nutritional products in the wider bone-health environment. A shared association with bones does not establish one pharmaceutical family, one route or the same documented role for every substance or product.

131 classified products